The CAPTAIN trial compared the MRI-Guided TULSA Procedure™ to robotic radical prostatectomy for localized prostate cancer.
AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target and destroy tissue without delivering excess heat and the unintended ...
Francis Medical has obtained $80 million in venture capital funding to support the development of its water vapor ablation therapy for cancers of the prostate, kidneys and bladder. The series C round ...
Add Yahoo as a preferred source to see more of our stories on Google. Francis Medical’s Vanquish device for treating intermediate-risk prostate cancer has been cleared by the US Food and Drug ...
MINNEAPOLIS, March 25, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical study) ...
Real-world oncologic data support whole gland ablation as primary treatment for appropriate patients with localized prostate cancer. Primary whole gland ablation results in good intermediate- to ...
MedPage Today on MSN
Ultrasound treatment for prostate cancer has early advantage versus prostatectomy
Better continence, erectile function, but data on oncologic outcomes still 2 years away ...
WASHINGTON -- Results from a long-term follow-up of the pivotal TACT trial showed that MRI-guided transurethral ultrasound ablation (TULSA) was effective and durable in men with localized prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results